PTC Therapeutics Q3 2023 Earnings Report

PTC Therapeutics EPS Results

• Actual EPS: -$1.76
• Consensus EPS: -$0.85
• Beat/Miss: Missed by -$0.91
• One Year Ago EPS: -$1.53

PTC Therapeutics Revenue Results

• Actual Revenue: $196.60 million
• Expected Revenue: $210.23 million
• Beat/Miss: Missed by -$13.63 million
• YoY Revenue Growth: -9.40%

PTC Therapeutics Announcement Details

• Quarter: Q3 2023
• Date: 10/26/2023
• Time: After Market Closes

PTC Therapeutics (NASDAQ:PTCT), a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.